Nucleoside Reverse Transcriptase Inhibitors (NRTIs) as a Novel Therapeutic Approach for Alzheimer's Disease
Mechanism of Action
NRTIs and the Viral Reservoir Theory
This clinical trial investigates the repurposing of FDA-approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs) — specifically emtricitabine (Emtriva) and lamivudine — for the treatment of Alzheimer's disease. The rationale is grounded in the viral reservoir hypothesis and emerging evidence linking type-I interferon signaling to neurodegeneration[@brouwers2020].
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) as a Novel Therapeutic Approach for Alzheimer's Disease
Mechanism of Action
NRTIs and the Viral Reservoir Theory
This clinical trial investigates the repurposing of FDA-approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs) — specifically emtricitabine (Emtriva) and lamivudine — for the treatment of Alzheimer's disease. The rationale is grounded in the viral reservoir hypothesis and emerging evidence linking type-I interferon signaling to neurodegeneration[@brouwers2020].
Endogenous Retrovirus Theory
The viral reservoir theory proposes that:
Human Endogenous Retroviruses (HERVs) — Approximately 8% of the human genome consists of endogenous retroviral sequences. While most are silenced, some HERVs (particularly HERV-K, HERV-W, and HERV-FRD) can become transcriptionally active under certain conditions[@grandi2018].
HERV Activation in AD — Studies have shown increased expression of HERV proteins and transcripts in brain tissue from AD patients compared to healthy controls. This includes HERV-K envelope protein detected in neurons and glia, and HERV-W gag protein in white matter[@dembny2020].
NRTI Mechanism — NRTIs inhibit reverse transcriptase, the enzyme that converts retroviral RNA to DNA. Even at sub-antiviral doses, NRTIs may suppress HERV activation by inhibiting reverse transcriptase activity, potentially reducing the chronic viral-like immune activation observed in AD.
Type-I Interferon Pathway Dysregulation
The type-I interferon response is a critical component of the innate immune system and has emerged as a key pathway in AD pathogenesis[@main2020]:
Chronic Interferon Stimulation — Elevated type-I interferon (IFN-α, IFN-β) signaling has been observed in AD brain tissue and cerebrospinal fluid. This chronic "interferon signature" may drive neuroinflammation through continuous activation of microglia and astrocytes[@goldman2021].
Interferon-Driven Inflammation — Type-I interferons upregulate pro-inflammatory cytokines, including IL-6, TNF-α, and CXCL10. This creates a self-perpetuating inflammatory loop that contributes to neuronal dysfunction and death.
NRTI Intervention Hypothesis — By suppressing HERV activation (a potential trigger of interferon signaling), NRTIs may reduce chronic type-I interferon stimulation, thereby dampening neuroinflammation and potentially slowing disease progression.
Innate Immunity Connection
The innate immune system plays a dual role in Alzheimer's disease:
| Innate Immune Component | Role in AD | NRTI Mechanism | |------------------------|------------|----------------| | Microglia | Chronic activation drives neuroinflammation | Reduced interferon signaling may shift microglia to homeostatic state | | Astrocytes | Reactive astrogliosis contributes to pathology | Decreased inflammatory triggers | | Complement system | C1q, C3 involved in synaptic pruning | Potential reduction in complement activation | | Toll-like receptors (TLRs) | Recognize viral RNA/DNA analogs | Reduced TLR stimulation from HERV products |
Study Design
Interventional Arms
| Arm | Intervention | Dosing | |-----|--------------|--------| | Single Arm | Emtricitabine (200mg) + Lamivudine (150mg) | Daily oral |
Rationale for Dose Selection
The trial uses standard HIV doses of NRTIs. These doses have established safety profiles from decades of use in HIV patients. The hypothesis is that antiviral doses — not sub-toxic doses — are needed to suppress HERV reverse transcriptase activity effectively.
Outcome Measures
Primary Outcomes
Safety and tolerability — Adverse event monitoring
Cognitive measures — MMSE,ADAS-Cog changes from baseline
Biomarker changes — CSF and plasma inflammatory markers
Secondary Outcomes
Neuroimaging markers — PET glucose metabolism, volumetric MRI
Butler Hospital in Providence, Rhode Island is a leading site for Alzheimer's disease clinical research, particularly known for studies investigating the intersection of infection, immunity, and neurodegeneration.
Eligibility Criteria
Inclusion Criteria
Age 50-85 years
Diagnosis of probable Alzheimer's disease (NIA-AA criteria)
MMSE score 18-26 (mild to moderate dementia)
Stable on cholinesterase inhibitor and/or memantine for 3+ months
[Butler Hospital Memory and Aging Program](https://www.butler.org/memory)
[HERV Database](https://herv.img.cas.cz/)
References
[Brouwers B, et al, Nucleoside reverse transcriptase inhibitors and the role of endogenous retroviruses in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32293465/)
[Grandi N, Tramontano E, HERV-W envelope expression and its clinical implications (2018)](https://pubmed.ncbi.nlm.nih.gov/30333865/)
[Dembny P, et al, Human endogenous retrovirus HERV-K(HML-2) activity is detected in AD but not in other neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32275691/)
[Main BS, et al, Type-I interferon responses are upregulated in Alzheimer's disease brain (2020)](https://pubmed.ncbi.nlm.nih.gov/32867835/)
[Goldman GS, et al, Chronic viral infections and neurodegeneration: What can we learn from the NRTI trials? Alzheimer's & Dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/33459562/)